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ABSTRACT
Objective  To assess the efﬁ  cacy and safety of 
golimumab over 104 weeks in patients with active 
ankylosing spondylitis.
Methods  At baseline, patients with active ankylosing 
spondylitis (n=356) were randomly assigned (1:1.8:1.8) 
to subcutaneous injections of placebo (group 1), 
golimumab 50 mg (group 2) or golimumab 100 mg 
(group 3) every 4 weeks. At week 16, patients in groups 
1 and 2 with <20% improvement in total back pain and 
morning stiffness entered early escape to 50 or 100 mg, 
respectively. At week 24, patients still receiving placebo 
crossed over to golimumab 50 mg. Findings through week 
24 were previously reported; those through week 104 are 
presented herein.
Results  At week 104, 38.5%, 60.1% and 71.4% of 
patients in groups 1, 2 and 3, respectively, had at least 
20% improvement in the Assessment in SpondyloArthritis 
international Society response criteria (ASAS20); 38.5%, 
55.8% and 54.3% had an ASAS40 response and 21.8%, 
31.9% and 30.7% were in ASAS partial remission. Mean 
Bath Ankylosing Spondylitis Disease Activity Index and 
Bath Ankylosing Spondylitis Functional Index scores were 
<3 at week 104 for all the treatment regimens. 
Golimumab safety through week 104 was similar to that 
through week 24.
Conclusion  Clinical response that was achieved by 
patients receiving golimumab through 24 weeks was 
sustained through 52 and 104 weeks. The golimumab 
safety proﬁ  le appeared to be consistent with the known 
safety proﬁ  le of tumour necrosis factor inhibitors.
Golimumab is a human monoclonal antibody to 
tumour necrosis factor (TNF) α that is administered 
subcutaneously every 4 weeks. We previously 
reported the 24-week results of the double-blind, 
randomised, placebo-controlled GO-RAISE (A 
Multicenter Randomized, Double-blind, Placebo-
controlled Trial of Golimumab, a Fully Human 
Anti-TNFα Monoclonal Antibody, Administered 
Subcutaneously, in Subjects with Active Ankylosing 
Spondylitis) study, in which we evaluated the efﬁ  -
cacy and safety of golimumab in patients with 
ankylosing spondylitis (AS).1 The primary end 
point of the GO-RAISE study was achieved; 59% of 
patients in the 50-mg group and 60% of patients in 
the 100-mg group achieved at least 20% improve-
ment in the Assessment in SpondyloArthritis 
international Society response criteria (ASAS20) 
at week 14 compared with 22% in the placebo 
group (p<0.001 for comparisons of placebo with 
each golimumab group). No unexpected adverse 
events were observed through 24 weeks of goli-
mumab treatment. Patients were followed up for 
up to 5 years, with the blind maintained through 
week 104 (for the type of treatment, placebo or 
golimumab, through week 24 and, following cross-
over, for the golimumab dose through week 104) to 
assess the long-term effects of golimumab therapy. 
Here we present the 104-week efﬁ  cacy and safety 
ﬁ  ndings from the GO-RAISE study.
PATIENTS AND METHODS
Details of the GO-RAISE study design, along with 
complete patient inclusion criteria, have been pre-
viously published.1 Brieﬂ   y, patients had AS, as 
deﬁ  ned according to the 1984 New York Criteria,2 
for at least 3 months before the ﬁ  rst administration 
of study agent and an inadequate response to cur-
rent or previous treatment with non-steroidal anti-
inﬂ  ammatory drugs (NSAIDs) or disease-modifying 
antirheumatic drugs (DMARDs). Patients were ran-
domly assigned in a 1:1.8:1.8 ratio to receive subcu-
taneous injections of placebo (group 1), golimumab 
50 mg (group 2) or golimumab 100 mg (group 3) 
every 4 weeks (ﬁ  gure 1). Concomitant use of meth-
otrexate, sulphasalazine, hydroxychloroquine, 
corticosteroids and NSAIDs at stable doses was 
permitted as previously described.1
At week 16, patients with less than 20% improve-
ment from baseline in total back pain and morning 
stiffness entered early escape, such that their study 
medication was adjusted in a double-blind fash-
ion. Patients in group 1 initiated treatment with 
golimumab 50 mg instead of placebo injections, 
and patients in group 2 had their golimumab dose 
increased from 50 to 100 mg; patients in group 3 
did not have their study medication adjusted even 
if they met the early escape criteria.
At week 24, all remaining patients in group 1 
who had been receiving placebo injections began 
receiving golimumab 50 mg; all other patients con-
tinued to receive their assigned treatment (from ran-
domisation or early escape). Injections continued 
to be administered subcutaneously every 4 weeks 
through week 100, with ﬁ   nal study assessments 
at week 104. While the placebo-controlled portion 
of the study ended at week 24, study participants 
and investigators remained blinded through week 
104 as to the golimumab dose (50 or 100 mg). After 
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replaced with the last non-missing value. Patients were categor-
ised according to their original randomly assigned treatment 
group. Thus, group 1 consisted of patients who were originally 
assigned to placebo and received golimumab 50 mg at week 
16 if they met the criteria for early escape or crossed over to 50 
mg at week 24. Group 2 comprised patients who were initially 
assigned to golimumab 50 mg and received that dose through-
out the study or received 100 mg at week 16 if they met the 
criteria for early escape. Group 3 comprised patients who were 
initially assigned to golimumab 100 mg and received that dose 
throughout the study.
2. By treatment regimen: treatment regimen 1 consisted of 
patients who were originally assigned to placebo at baseline 
and who either entered early escape at week 16 to receive 
golimumab 50 mg through week 104 or crossed over at week 
24 to receive golimumab 50 mg through week 104. Treatment 
regimen 2 consisted of patients who were originally assigned 
to golimumab 50 mg at baseline and who either entered early 
escape at week 16 to receive golimumab 100 mg through week 
104 or continued 50 mg through week 104. Treatment regi-
men 3 consisted of patients who were originally assigned to 
golimumab 100 mg at baseline and who did not receive study 
medication adjustments. Concomitant medications were stable 
through week 24, but selected medications could be adjusted 
after week 24 (see Methods for details). Actual observed 
ASAS20 and ASAS40 response rates through week 104 are 
presented without data imputation. Patients who entered 
early escape were counted in the treatment regimen to which 
they were originally assigned. Efﬁ  cacy data (ASAS20; ASAS40; 
BASDAI50 and changes in BASDAI, BASFI, BASMI and SF-36 
scores) are also presented by actual treatment received based 
on the early escape status (see table 1 for categories).
RESULTS
A total of 356 patients were randomly assigned to treatment 
(ﬁ  gure 2). Baseline disease characteristics of the study population 
week 52, patients were allowed to inject the study agent at home 
and were asked to return for study visits every 12 weeks. Serum 
samples were collected at weeks 24, 52 and 104 and assessed 
for the presence of antibodies to golimumab using a previously 
described assay.3
The protocol was reviewed and approved by the institutional 
review board or independent ethics committee at each site. All 
patients gave written informed consent.
We evaluated the response to treatment by determin-
ing the proportions of patients with an ASAS20 or ASAS40 
response, ASAS partial remission (deﬁ  ned as a value below 2 
in each of the four ASAS domains) and at least 50% improve-
ment in the Bath Ankylosing Spondylitis Disease Activity 
Index4 (BASDAI50 response). Changes from baseline in the 
Bath Ankylosing Spondylitis Functional Index (BASFI),5 Bath 
Ankylosing Spondylitis Metrology Index (BASMI) based on a 
linear method6 7 and physical and mental component summary 
(PCS and MCS, respectively) scores of the 36-item Short-Form 
Health Survey (SF-36)8 were used to assess physical function, 
range of motion and health-related quality of life, respectively. 
The proportions of patients achieving an Ankylosing Spondylitis 
Disease Activity Score (ASDAS)9 <1.1 (indicating inactive dis-
ease) or <2.1 (indicating moderate disease activity) were also 
determined. This was performed as a post hoc analysis, as this 
measure was designed following the start of this trial.
No statistical comparisons were made for efﬁ  cacy results after 
week 24 because all patients were receiving golimumab. Efﬁ  cacy 
data are presented using two approaches:
1.  Intention to treat: patients who met the treatment failure cri-
teria at week 141 and those who entered early escape at week 
16 were considered to be non-responders at week 104. In addi-
tion, patients who discontinued treatment because of an unsat-
isfactory therapeutic effect after week 24 or who were missing 
all ASAS components were considered to be non-responders 
at week 104. For patients who did not meet the treatment fail-
ure criteria, the missing ASAS components at week 104 were 
Figure 1  Study schema showing randomisation (A) and major study time points (B).
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Efﬁ  cacy
The intention to treat analysis revealed that 38.5% of patients 
in group 1, 60.1% in group 2 and 71.4% in group 3 had an 
ASAS20 response at week 104. In addition, 38.5% of patients in 
group 1, 55.8% in group 2 and 54.3% in group 3 had an ASAS40 
response, and 21.8%, 31.9% and 30.7%, respectively, were in 
partial remission.
Actual observed efﬁ  cacy outcomes at weeks 28, 52 and 104, 
without data imputation, are summarised in table 1 according 
to early escape status. Patients who required early escape at 
week 16 generally had lower response rates than those in the 
same group who did not require early escape. However, of the 
patients in group 2 who met the early escape criteria, 42.9% 
and 43.8% achieved ASAS20 responses at weeks 52 and 104, 
respectively, after receiving a dose escalation from 50 to 100 mg 
(table 1). Of the patients in group 3 who met the early escape 
criteria, 35.7% and 56.0% achieved ASAS20 responses at weeks 
52 and 104, respectively, even though they did not receive dose 
adjustments.
and patient disposition through week 24 have been previously 
published.1 At baseline, 28 (35.9%) patients in group 1, 43 
(29.1%) patients in group 2 and 44 (31.4%) patients in group 3 
used concomitant DMARDs. At week 52, a total of 313 patients 
(group 1, n=70; group 2, n=118; group 3, n=125) were still receiv-
ing treatment, and 290 patients (group 1, n=65; group 2, n=109; 
group 3, n=116) completed the study through week 104.
At week 16, 41 (53%) patients in group 1 and 25 (18%) 
patients in group 2 had less than 20% improvement in total back 
pain and morning stiffness and entered early escape. Thirty-
three (24%) patients in group 3 met the criteria for early escape 
at week 16, but as speciﬁ  ed in the protocol, they did not have 
their dose adjusted.
Through week 104, 13 (17%) patients in group 1, 28 (20%) 
patients in group 2 and 24 (17%) patients in group 3 discontinued 
treatment. The most common reasons for discontinuation of the 
study agent were unsatisfactory therapeutic effect (27 patients: 8 
in group 1, 11 in group 2 and 8 in group 3) and adverse events (19 
patients: 2 in group 1, 7 in group 2 and 10 in group 3).
Table 1  Efﬁ  cacy measures through week 104 by early escape status: observed data presented without imputation





(week 24–104)† 50 mg only‡
Early escape 
(week 16–104) 
50 mg →100 mg* 100 mg only‡ 100 mg → 100 mg*
Randomised patients (n) 41 35 113 25 107 33
ASAS20
  Week 28 23/40 (57.5) 26/35 (74.3) 85/102 (83.3) 6/25 (24.0) 78/100 (78.0) 3/32 (9.4)
  Week 52 25/34 (73.5) 29/34 (85.3) 85/98 (86.7) 9/21 (42.9) 86/99 (86.9) 10/28 (35.7)
  Week 104 24/31 (77.4) 28/31 (90.3) 77/90 (85.6) 7/16 (43.8) 77/93 (82.8) 14/25 (56.0)
ASAS40
  Week 28 15/40 (37.5) 21/35 (60.0) 66/102 (64.7) 3/25 (12.0) 70/100 (70.0) 2/32 (6.3)
  Week 52 19/34 (55.9) 27/34 (79.4) 73/98 (74.5) 2/21 (9.5) 73/99 (73.7) 8/28 (28.6)
  Week 104 21/31 (67.7) 28/31 (90.3) 74/90 (82.2) 5/16 (31.3) 64/93 (68.8) 7/25 (28.0)
BASDAI50
  Week 28 17/41 (41.5) 21/35 (60.0) 65/103 (63.1) 3/25 (12.0) 66/100 (66.0) 1/32 (3.1)
  Week 52 17/35 (48.6) 27/34 (79.4) 70/99 (70.7) 1/21 (4.8) 76/99 (76.8) 6/29 (20.7)
  Week 104 21/33 (63.6) 27/32 (84.4) 72/91 (79.1) 5/16 (31.3) 65/93 (69.9) 6/25 (24.0)
Change in BASDAI§
 Week  28 −2.4±2.49 −3.3±2.47 −3.8±2.15 −0.8±1.88 −3.9±2.41 −0.5±1.55
 Week  52 −3.4±2.60 −4.4±2.02 −4.0±2.09 −1.3±1.58 −4.4±2.24 −1.3±1.96
 Week  104 −3.6±2.25 −4.6±2.42 −4.2±2.19 −2.0±2.33 −4.4±2.25 −1.8±1.93
Change in BASFI§
 Week  28 −1.5±2.86 −1.5±2.30 −2.4±2.12 −0.3±1.52 −2.5±2.26 0.6±2.48
 Week  52 −3.0±3.07 −2.3±2.24 −2.5±2.12 −0.9±1.59 −2.9±2.14 −0.5±2.63
 Week  104 −3.2±3.20 −2.6±2.23 −2.7±2.07 −1.7±2.19 −2.9±2.21 −1.2±2.64
Change in BASMI§
 Week  52 −0.7±0.87 −0.8±0.90 −0.7±0.90 −0.4±0.79 −0.7±0.88 0.0±1.07
 Week  76 −0.7±0.96 −0.7±0.94 −0.8±0.78 −0.4±0.92 −0.7±0.88 −0.2±0.92
 Week  104 −0.6±1.04 −0.8±0.95 −0.8±0.79 −0.4±0.98 −0.8±0.96 −0.3±0.86
Change in SF-36 PCS¶
 Week  52 12.3±8.78 14.1±9.40 12.8±10.63 4.8±8.96 13.0±8.14 5.4±8.62
 Week  76 12.7±10.87 15.2±8.65 13.4±10.70 7.3±10.82 13.5±8.73 6.6±7.49
 Week  104 13.6±7.80 15.5±9.32 14.2±11.28 7.6±8.83 13.9±9.28 6.5±7.77
Change in SF-36 MCS¶
 Week  52 4.3±11.51 3.7±8.80 3.7±7.90 1.8±9.80 6.4±11.75 1.3±9.93
 Week  76 3.9±12.27 3.9±9.12 2.9±9.00 1.2±8.58 7.3±10.81 2.8±11.26
 Week  104 5.2±10.94 2.0±9.55 3.8±8.75 1.5±13.82 7.6±10.86 5.0±9.86
Values are mean±SD change from baseline for continuous outcomes or n (%) of patients achieving the end point for dichotomous outcomes.
*Patients in these groups met the early escape criteria at week 16.
†Patients in this group did not discontinue study agent prior to week 24 and crossed over at week 24.
‡Patients in these groups did not meet the early escape criteria at week 16.
§Negative change indicates improvement.
¶Positive change indicates improvement.
ASAS, Assessment in SpondyloArthritis international Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; 
BASMI, Bath Ankylosing Spondylitis Metrology Index; MCS, mental component summary; PCS, physical component summary; SF-36, 36-item Short-Form health survey.
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who received at least one dose of golimumab are summarised 
in table 2. Adverse events were attributed to the dose that the 
patients were receiving at the time of the event. Thus, patients 
are counted in the treatment group in which they were assigned 
at the time of the event. The proportions of patients with at least 
one adverse event generally increased with longer average dura-
tion of follow-up. More patients who received the 100 mg dose 
of golimumab at any point during the trial had one or more seri-
ous adverse events (24 [14.5%] of 165) and serious infections (7 
[4.2%] of 165) compared with patients who received golimumab 
50 mg (16 [8.0%] of 213 and 3 [1.4%] of 213, respectively).
Through week 104, infections were reported in 37.7% 
of patients who had received placebo, 62.0% of those who 
had received golimumab 50 mg and 70.9% of those who had 
received golimumab 100 mg; serious infections were reported in 
1.3%, 1.4% and 4.2% of patients, respectively (table S2). The 
incidence of infections per 100 patient-years in patients receiv-
ing golimumab 50 mg was similar to that for patients receiving 
placebo. A dose-dependent trend in the rate of infections and 
serious infections was noted for the two golimumab doses. 
However, when comparing the incidence per 100 patient-years 
of infection, serious infection or upper respiratory tract infection, 
the 95% CIs for the two golimumab doses overlapped and thus 
showed no apparent dose effect.
No patients died through week 104 of the study. Serious infec-
tions were similar in nature and frequency to those observed in 
the ﬁ  rst 24 weeks of the study. Serious infections that occurred 
after week 24 included the following events: urosepsis and 
clostridial infection in group 1 (one patient each); tonsillitis (one 
patient) and anal abscess (two events in one patient) in group 2; 
and infectious bursitis, cellulitis, Lyme disease and pulmonary 
The proportions of patients with ASDAS scores <1.1 or <2.1 at 
week 24, 52 or 104 are summarised according to the original ran-
domised treatment groups (table S1). Signiﬁ  cantly greater propor-
tions of patients in group 2 and group 3 had ASDAS scores <1.1 or 
<2.1 at week 24 when compared with patients in group 1.
Observed ASAS20 and ASAS40 responses for each treatment 
regimen over time through week 104 are shown in ﬁ  gure 3. Mean 
BASDAI, BASMI (range of motion) and BASFI values over time 
through week 104 are shown in ﬁ  gure 4. By week 104, all treat-
ment regimens led to mean BASDAI and BASFI scores that were 
less than 3. However, scores were reduced earlier in patients who 
were originally treated with golimumab from week 0 compared 
with those who initially received placebo and later crossed over 
to golimumab. Similarly, the mean BASMI score improved to less 
than 3 at week 104 for patients who received golimumab from 
week 0 through week 104, compared with a mean BASMI score of 
3.17 for those patients who were assigned to placebo initially and 
who later entered early escape or crossed over to golimumab.
Observed proportions of patients achieving a BASDAI50 
response, as well as actual changes from baseline in BASFI, 
BASMI (linear method) and PCS and MCS scores of the SF-36 
(health-related quality of life) are summarised in table 1 for 
patients in each group according to their early escape status. 
Consistent with clinical efﬁ  cacy as assessed by ASAS response 
criteria, patients who required early escape at week 16 gener-
ally had lower response rates or less improvement from baseline 
than those in the same group who did not require early escape.
Safety
Safety results through week 24 were previously reported.1 
Adverse events from baseline through week 104 for patients 
Figure 2  Patient disposition through week 104. AEs, adverse events.
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Figure 4  Mean BASDAI, BASMI and BASFI scores through week 104. 
Treatment regimen 1 consisted of patients who were originally assigned 
to placebo at baseline and who either entered early escape at week 16 
to receive golimumab 50 mg through week 104 or crossed over at week 
24 to receive golimumab 50 mg through week 104. Treatment regimen 2 
consisted of patients who were originally assigned to golimumab 50 mg 
at baseline and who either entered early escape at week 16 to receive 
golimumab 100 mg through week 104 or continued 50 mg through week 
104. Treatment regimen 3 consisted of patients who were originally 
assigned to golimumab 100 mg at baseline and who did not receive 
study medication adjustments. Observed data are presented without 
imputation. BASDAI, Bath Ankylosing Spondylitis Disease Activity 
Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, 
Bath Ankylosing Spondylitis Metrology Index.
tuberculosis (one patient for each event) and pelvic inﬂ  amma-
tory disease and endometriosis of the appendix (both in the 
same patient) in group 3. The patient with tuberculosis was 
negative at screening according to QuantiFERON and tubercu-
lin testing. No opportunistic infections were reported through 
week 104. However, one patient in group 2 had coccidiomycosis 
after week 104.
As previously noted,1 two patients, one each from groups 1 
and 3, had basal cell carcinoma reported prior to week 24. No 
additional malignancies were reported past week 24.
Injection-site reactions occurred in 7.3% of patients in group 
1 who entered early escape, 8.8% of patients in group 1 who 
crossed over to active treatment at week 24, 24.0% of patients 
in group 2 who entered early escape, 8.0% of patients in group 
2 who did not enter early escape and 11.4% of patients in group 
3 (table 2) and mostly comprised injection-site erythema and 
swelling. No injection-site reactions were considered to be seri-
ous or resulted in discontinuation of study agent.
Liver enzyme elevations were more common in patients who 
received golimumab 100 mg than in those who received the 
50 mg dose. While 2.8% of all patients had markedly abnor-
mal elevations of alanine aminotransferase levels, no patient had 
concomitant markedly abnormal postbaseline elevations of ala-
nine/aspartate aminotransferase (at least three times the upper 
limit of normal) and total bilirubin (at least two times the upper 
limit of normal).
Ten patients were found to be positive for antibodies to goli-
mumab through week 24. Of these, ﬁ  ve (50%) patients changed 
from positive to negative between weeks 24 and 104. It is unclear 
if antibodies to golimumab had an effect on treatment response.
DISCUSSION
The 2-year results of the GO-RAISE trial indicate that the 
improvements in signs and symptoms, physical function, range 
of motion and health-related quality of life achieved at week 241 
by patients with AS who received golimumab were sustained 
Figure 3  The proportions of patients who had an ASAS20 or ASAS40 
response through week 104. Treatment regimen 1 consisted of patients 
who were originally assigned to placebo at baseline and either entered 
early escape at week 16 to receive golimumab 50 mg through week 104 
or crossed over at week 24 to receive golimumab 50 mg through week 
104. Treatment regimen 2 consisted of patients who were originally 
assigned to golimumab 50 mg at baseline and either entered early 
escape at week 16 to receive golimumab 100 mg through week 104 or 
continued 50 mg through week 104. Treatment regimen 3 consisted of 
patients who were originally assigned to golimumab 100 mg at baseline 
and did not receive study medication adjustments. Observed data are 
presented without imputation. ASAS20, at least 20% improvement 
in the Assessment of SpondyloArthritis international Society (ASAS) 
criteria; ASAS40, at least 40% improvement in the criteria.
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at week 16 than those in the other groups. Patients in this group 
who entered early escape at week 16 or subsequently crossed 
over to golimumab 50 mg at week 24 demonstrated patterns 
of response after receiving active treatment that were similar to 
those observed in patients initially randomised to golimumab. 
Of the few patients who required early escape in group 2 (goli-
mumab 50 mg), almost half (44%) achieved an ASAS20 response 
at week 104. However, the beneﬁ  t of dose escalation from goli-
mumab 50 mg to 100 mg cannot be fully elucidated from this 
study because there was no comparison with patients who met 
the criteria for early escape but remained on golimumab 50 mg. 
The proportion of patients in group 3 (golimumab 100 mg) who 
met the criteria for early escape at week 16 was similar to that 
of group 2, as were the ASAS20 response rates at week 104 for 
both early escape subgroups.
Safety results through week 104 were similar to those through 
week 24 in that golimumab was generally well tolerated, and 
adverse event patterns were consistent with the known safety 
proﬁ  le of TNF inhibitors. The increased rate of serious infec-
tions with the 100 mg dose of golimumab in this study is consis-
tent with results of previous studies of TNF inhibitors in which 
patients receiving higher doses had a greater risk of serious 
infections compared with patients receiving lower doses.10 11 
Although patients with active AS may derive additional beneﬁ  t 
from the 100 mg dose, the possibly increased risk of serious infec-
tions compared with the 50 mg dose should be considered.
This analysis was limited by the lack of a placebo compara-
tor group after week 24; because of the placebo crossover, all 
patients received blinded, active treatment from week 24 to 
or improved through week 104. This was demonstrated even 
by the conservative analysis in which patients who met vari-
ous treatment failure criteria, including early escape, were con-
sidered to be non-responders throughout the remainder of the 
study. Improvement was generally similar between the two 
golimumab doses for the end points assessed.
In addition to the original treatment assignments, the study 
protocol included treatment adjustments at week 16 based on 
patients’ improvement in the total back pain score and morning 
stiffness (ie, early escape) that included crossover from placebo 
to active treatment or dose escalation from 50 to 100 mg. The 
ﬁ  ndings showed that among patients who received golimumab 
from the beginning of the study and who did not meet the early 
escape criteria, greater proportions achieved ASAS20, ASAS40 
and BASDAI50 responses, and improvements in BASFI, BASMI, 
and PCS and MCS scores of the SF-36 (health-related quality 
of life) were greater than those in patients who required early 
crossover or dose escalation. Furthermore, an increase in goli-
mumab dose from 50 to 100 mg in group 2 patients who entered 
early escape did not appear to substantially increase response 
rates in this subset of patients. Thus, given the consistency of 
these ﬁ  ndings across parameters, patients who required early 
escape may have had more refractory disease. Another implica-
tion of this ﬁ  nding is that patients with AS who do not improve 
by even 20% in total back pain score and morning stiffness after 
16 weeks of treatment may have a reduced likelihood of 
responding to continued golimumab treatment.
As expected, patients in group 1 who received placebo during 
the ﬁ  rst part of the study were more likely to require early escape 
Table 2  Summary of adverse events through week 104*
Placebo → golimumab 50 mg 
(group 1)
Golimumab 50 mg 
(group 2)





(week 24–104)‡ 50 mg only§
Early escape 
(50 mg →100 mg)† 100 mg¶ All golimumab
Patients treated with golimumab 41 34 138 25 140 353
Mean duration of follow-up (weeks) 79.0 77.6   79.2 72.0   95.9   90.7
Mean exposure (number of administrations) 19.1 18.6   19.2 17.1   23.0   21.8
Patients with one or more adverse events 36 (87.8) 29 (85.3) 130 (94.2) 23 (92.0) 135 (96.4) 332 (94.1)
Patients with one or more serious adverse events 4 (9.8) 2 (5.9)   10 (7.2) 3 (12.0)   21 (15.0)   40 (11.3)
Patients who discontinued study agent due to an 
adverse event
1 (2.4) 0 (0.0)     6 (4.3) 2 (8.0)   10 (7.1)   19 (5.4)
Patients with one or more infections 28 (68.3) 10 (29.4)   90 (65.2) 17 (68.0) 101 (72.1) 241 (68.3)
Patients with one or more serious infections 2 (4.9) 0 (0.0) 1 (0.7) 1 (4.0)     6 (4.3)   11 (3.1)
Patients with one or more injection-site reactions 
to golimumab
3 (7.3) 3 (8.8) 11 (8.0) 6 (24.0)   16 (11.4)   38 (10.8)
Injections with one or more injection-site 
reactions to golimumab
3/784 (0.4) 19/634 (3.0)   16/2640 (0.6) 29/427 (6.8)   39/3220 (1.2) 106/7705 (1.4)
Patients with one or more malignancies 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7)     2 (0.6)
Patients with markedly abnormal**:
  Alanine aminotransferase 1 (2.4) 1 (2.9) 1 (0.7) 0 (0.0) 7 (5.0)   10 (2.8)
  Aspartate aminotransferase 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 4 (2.9)     5 (1.4)
  Total bilirubin 0 (0.0) 1 (2.9) 4 (2.9) 0 (0.0) 3 (2.1) 8 (2.3)
Patients negative for antinuclear antibodies at 
baseline
31 27  80 14  90 232
    Patients positive for antinuclear antibodies 
at week 104
1 (3.2) 3 (11.1) 2 (2.5) 1 (7.1) 5 (5.6)   11 (4.7)
    Patients positive for anti-double-stranded 
DNA at week 104
1 (100) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)     1 (9.1)
Data presented as n (%) unless otherwise noted.
*Patients are counted in the dosing group in which they were assigned at the time of the event.
†Patients in these groups met the early escape criteria at week 16.
‡Patients in this group did not discontinue study agent prior to week 24 and crossed over at week 24.
§This group included patients randomised to golimumab 50 mg irrespective of early escape status. Adverse events for patients who met early escape are only counted up to week 16.
¶This group included all patients randomised to golimumab 100 mg.
**Predeﬁ  ned as postbaseline values of ≥2 times the baseline value and >150 IU/mL (alanine/aspartate aminotransferase) or ≥2 times the baseline value and >1.5 mg/dl (total 
bilirubin).
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104. In addition, because of the long-term nature of the study, 
approximately 19% of patients discontinued treatment by week 
104, with unsatisfactory therapeutic effect and adverse events 
being the most common reasons for discontinuation. However, 
290 patients completed the study through week 104 and were 
included in the results presented here.
The results of this study suggest that subcutaneous injec-
tions of golimumab every 4 weeks were effective in reducing 
the signs and symptoms of AS in patients with active disease 
despite prior treatment with NSAIDs or DMARDs, as well as in 
sustaining improvement in physical function, range of motion 
and health-related quality of life through week 104. Patients 
who completed the 2-year study will continue to be followed 
for up to 5 years to allow for a long-term analysis of the effects 
of golimumab in patients with AS. In addition, the effect of 
golimumab on radiographic end points including MRI was also 
evaluated, and these results will be reported separately. The sus-
tained improvement in the signs and symptoms of AS in the cur-
rent analysis is consistent with 2-year studies of other anti-TNF 
agents,12–14 and the safety proﬁ  le of golimumab appeared to be 
consistent with the known safety proﬁ  le of TNF inhibitors.
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